# **Listing of Claims**

Claims 1-35 (Previously Canceled)

## 36. (Amended) A compound of the formula

$$X_1 \xrightarrow{N} O$$

$$X_1 \xrightarrow{N} O$$

$$R_5$$

or a pharmaceutically acceptable salt thereof, wherein

L and M are independently selected from O ,  $-CH_2$ -, -S-, -N(R) N(R) , C(=O)-,  $-SO_2$ -;

L is -O-;

# M is $-CH_2$ -:

 $X_1$ ,  $X_2$ ,  $X_a$ ,  $X_b$ ,  $X_c$ ,  $X_d$ , and  $X_e$  at are independently selected from -C(O)NR<sub>6</sub>R<sub>7</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)NR<sub>6</sub>R<sub>7</sub>, -NR<sub>6</sub>R<sub>7</sub>, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyl, C<sub>1</sub>-C<sub>4</sub> dihydroxyalkyl, H, halogen, haloalkyl, alkyl, haloalkoxy, heteroaryl, heterocycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, R<sub>6</sub>R<sub>7</sub>N-(C<sub>1</sub>-C<sub>6</sub> alkyl)-, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)alkyl, -N(R)C(O)NR<sub>6</sub>R<sub>7</sub>, -N(R)C(O)-(C<sub>1</sub>-C<sub>6</sub>)alkoxy, CO<sub>2</sub>R-(C<sub>1</sub>-C<sub>6</sub> alkyl)-, or -SO<sub>2</sub>NR<sub>6</sub>R<sub>7</sub>; wherein the heteroaryl and heterocycloalkyl groups are optionally substituted with -NR<sub>6</sub>R<sub>7</sub>, -C(O)NR<sub>6</sub>R<sub>7</sub>, R<sub>6</sub>R<sub>7</sub>N-(C<sub>1</sub>-C<sub>6</sub> alkyl)-, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or halogen; or

 $R_5$  is heteroaryl or heteroarylalkyl, wherein the heteroaryl and heteroaryl groups are optionally substituted with 1,2, 3, or 4 groups that are independently -C(O)NR<sub>6</sub>R<sub>7</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)NR<sub>6</sub>R<sub>7</sub>, -NR<sub>6</sub>R<sub>7</sub>, hydroxy(C<sub>1</sub>-C<sub>4</sub>)alkyl, C<sub>1</sub>-C<sub>4</sub> dihydroxyalkyl, H, OH,

halogen, haloalkyl, alkyl, haloalkoxy,  $R_6R_7N$ - $(C_1$ - $C_6$  alkyl)-, - $CO_2$ - $(C_1$ - $C_6$ )alkyl, - $N(R)C(O)NR_6R_7$ , or -N(R)C(O)- $(C_1$ - $C_6$ )alkoxy; wherein

R<sub>6</sub> and R<sub>7</sub> are independently at each occurrence H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, OH, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub> dihydroxyalkyl, C<sub>1</sub>-C<sub>6</sub> thiohydroxyalkyl, -(C<sub>1</sub>-C<sub>4</sub>)alkyl-CO<sub>2</sub>-alkyl, pyridyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkanoyl, benzyl, phenyl C<sub>1</sub>-C<sub>6</sub> alkoxy, or phenyl C<sub>1</sub>-C<sub>6</sub> alkanoyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently, halogen, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, piperidinyl C<sub>1</sub>-C<sub>6</sub> alkyl, morpholinyl C<sub>1</sub>-C<sub>6</sub> alkyl, piperazinyl C<sub>1</sub>-C<sub>6</sub> alkyl, OH, SH, NH<sub>2</sub>, NH(alkyl), N(alkyl)(alkyl), -O-C<sub>1</sub>-C<sub>4</sub> alkanoyl, C<sub>1</sub>-C<sub>4</sub> alkyl, CF<sub>3</sub>, or OCF<sub>3</sub>; or

 $R_6$ ,  $R_7$ , and the nitrogen to which they are attached form a morpholinyl, thiomorpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl ring which is optionally substituted with 1 or 2 groups that are independently  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, hydroxy, hydroxy  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  dihydroxyalkyl, or halogen;

R at each occurrence is independently H or C<sub>1</sub>-C<sub>6</sub> alkyl; and

Y, Y<sub>1</sub>, Y<sub>2</sub>, Y<sub>3</sub>, and Y<sub>4</sub> are independently selected from H, halogen, alkyl, carboxaldehyde, hydroxyalkyl, dihydroxyalkyl, alkenyl, alkynyl, CN, alkanoyl, alkoxy, alkoxyalkyl, haloalkyl, and carboxyl.

# 37. (Original) The compound according to claim 36 of the formula

$$X_1$$
 $X_1$ 
 $X_2$ 
 $X_2$ 
 $X_1$ 
 $X_2$ 
 $X_3$ 
 $X_4$ 
 $X_5$ 

or a pharmaceutically acceptable salt thereof.

#### 38. (Original) A compound according to claim 37, wherein

$$Xa$$
 $Xb$ 
 $Xb$ 
 $Xd$ 
 $Xb$ 
 $Xd$ 
 $Xb$ 
 $Xd$ 
 $Xd$ 
 $Xd$ 
 $Xd$ 
 $Xd$ 
 $Xd$ 
 $Xd$ 

Claims 39-49 (Canceled)

### 50. (Original) The compound according to claim 38, wherein

X<sub>a</sub> is hydrogen;

two of  $X_b$ ,  $X_c$ , and  $X_d$  are hydrogen and the other is  $-C(O)NR_6R_7$ ,  $-(C_1-C_6 \text{ alkyl})-C(O)NR_6R_7$ ,  $-NR_6R_7$ ,  $R_6R_7N-(C_1-C_6 \text{ alkyl})-$  or  $-CO_2-(C_1-C_6)$  alkyl; wherein

 $R_6$  and  $R_7$  are independently at each occurrence H,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_1$ - $C_6$  alkoxy  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxycarbonyl, OH,  $C_1$ - $C_6$  hydroxyalkyl,  $C_1$ - $C_6$  dihydroxyalkyl, -( $C_1$ - $C_4$ )alkyl- $CO_2$ -alkyl, pyridyl  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkanoyl, benzyl, phenyl  $C_1$ - $C_6$  alkoxy, or phenyl  $C_1$ - $C_6$  alkanoyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently, halogen,  $C_3$ - $C_6$  cycloalkyl,  $C_1$ - $C_6$  alkoxy, piperidinyl  $C_1$ - $C_6$  alkyl, morpholinyl  $C_1$ - $C_6$  alkyl, piperazinyl  $C_1$ - $C_6$  alkyl, OH, NH<sub>2</sub>, NH(alkyl), N(alkyl)(alkyl), -O- $C_1$ - $C_4$  alkanoyl,  $C_1$ - $C_4$  alkyl, CF<sub>3</sub>, or OCF<sub>3</sub>; or

 $R_6$ ,  $R_7$ , and the nitrogen to which they are attached form a morpholinyl, piperidinyl, pyrrolidinyl, or piperazinyl ring which is optionally substituted with 1 or 2 groups that are independently  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  alkoxy, hydroxy, hydroxy  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  dihydroxyalkyl, or halogen; and

X<sub>e</sub> is hydrogen, methyl, C<sub>1</sub>-C<sub>2</sub> alkoxy, or halogen.

### 51. (Original) The compound according to claim 50, wherein

 $X_b$  is  $-C(O)NR_6R_7$ ,  $-(C_1-C_6$  alkyl)- $C(O)NR_6R_7$ ,  $-NR_6R_7$ , or  $R_6R_7N$ - $(C_1-C_6$  alkyl)-wherein

 $R_6$  is hydrogen or  $C_1$ - $C_4$  alkyl;

 $R_7$  is OH,  $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkanoyl, wherein the alkyl and alkanoyl groups substituted with 1, 2, or 3 groups that are independently NH<sub>2</sub>, NH( $C_1$ - $C_6$  alkyl), N( $C_1$ - $C_6$  alkyl),  $C_3$ - $C_6$  cycloalkyl, OH, or  $C_1$ - $C_4$  alkoxy.

# 52. (Original) The compound according to claim 38, wherein

X<sub>a</sub> is halogen or methyl;

 $X_b$  is H,  $-NR_6R_7$ ,  $R_6R_7N_7-(C_1-C_6)$  alkyl)-,  $-C(O)NR_6R_7$ , or  $-CO_2-(C_1-C_6)$  alkyl;

 $X_c$  is -NR<sub>6</sub>R<sub>7</sub>, R<sub>6</sub>R<sub>7</sub>N-(C<sub>1</sub>-C<sub>6</sub> alkyl)-, -C(O)NR<sub>6</sub>R<sub>7</sub>, halogen, -CO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>6</sub> alkyl), N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -SO<sub>2</sub>N(C<sub>1</sub>-C<sub>6</sub> alkyl)(C<sub>1</sub>-C<sub>6</sub> alkyl), or piperazinyl, wherein the piperazinyl group is optionally substituted with 1 or 2 groups that are independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, hydroxy, hydroxy C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> dihydroxyalkyl, or halogen;

X<sub>d</sub> is hydrogen; and

 $X_e$  is H, methyl,  $NH_2$ ,  $NH(C_1-C_6$  alkyl) or  $N(C_1-C_6$  alkyl)( $C_1-C_6$  alkyl).

# 53. (Original) The compound according to claim 38, wherein

 $X_1$ ,  $X_2$ ,  $X_a$ ,  $X_b$ ,  $X_c$ ,  $X_d$ , and  $X_e$  are independently selected from H, OH, halogen, CF<sub>3</sub>, alkyl, OCF<sub>3</sub>, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, thienyl, furyl, pyrrolyl, piperidinyl, piperazinyl, or C<sub>3</sub>-C<sub>7</sub> cycloalkyl, wherein each of the above is optionally substituted with -NR<sub>6</sub>R<sub>7</sub>, -C(O)NR<sub>6</sub>R<sub>7</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)NR<sub>6</sub>R<sub>7</sub>, R<sub>6</sub>R<sub>7</sub>N-(C<sub>1</sub>-C<sub>6</sub> alkyl)-, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, or halogen.

### 54. (Original) The compound according to claim 37, wherein

 $R_5$  is a heteroaryl or heteroarylalkyl group, where each heteroaryl is pyrazolyl, imidazolyl, furanyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, dihydroindolyl, dihydroisoindolyl, indolon-2-yl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, or indolyl, each of which is optionally substituted with 1, 2, 3, or 4 groups that are independently  $-C(O)NR_6R_7$ ,  $-(C_1-C_4$  alkyl)- $-C(O)NR_6R_7$ ,  $-NR_6R_7$ , hydroxy( $-C_1-C_4$ )alkyl,  $-C_1-C_4$  dihydroxyalkyl, hydrogen, hydroxy, halogen, haloalkyl, alkyl, haloalkoxy,  $-C_1-C_6$  alkyl)-,  $-CO_2-(C_1-C_6)$ alkyl,  $-N(R)C(O)NR_6R_7$ , or  $-N(R)C(O)-(C_1-C_6)$ alkoxy; wherein

R<sub>6</sub> and R<sub>7</sub> are independently at each occurrence H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxycarbonyl, OH, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>6</sub> dihydroxyalkyl, C<sub>1</sub>-C<sub>6</sub> thiohydroxyalkyl, -(C<sub>1</sub>-C<sub>4</sub>)alkyl-CO<sub>2</sub>-alkyl, pyridyl C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkanoyl, benzyl, phenyl C<sub>1</sub>-C<sub>6</sub> alkoxy, or phenyl C<sub>1</sub>-C<sub>6</sub> alkanoyl, wherein each of the above is unsubstituted or substituted with 1, 2, or 3 groups that are independently, halogen, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, piperidinyl C<sub>1</sub>-C<sub>6</sub> alkyl, morpholinyl C<sub>1</sub>-C<sub>6</sub> alkyl, piperazinyl C<sub>1</sub>-C<sub>6</sub> alkyl, OH, SH, NH<sub>2</sub>, NH(alkyl), N(alkyl)(alkyl), -O-C<sub>1</sub>-C<sub>4</sub> alkanoyl, C<sub>1</sub>-C<sub>4</sub> alkyl, CF<sub>3</sub>, or OCF

- 55. (Original) The compound according to claim 54, wherein
  - Y<sub>2</sub>, Y<sub>4</sub>, and Y are independently halogen; and

 $Y_1$  and  $Y_3$  are both hydrogen.

56. (Original) The compound according to claim 55, wherein

 $X_1$  and  $X_2$  are independently H, methyl, -NR<sub>6</sub>R<sub>7</sub>, R<sub>6</sub>R<sub>7</sub>N-(C<sub>1</sub>-C<sub>6</sub> alkyl)-, -C(O)NR<sub>6</sub>R<sub>7</sub>, -(C<sub>1</sub>-C<sub>4</sub> alkyl)-C(O)NR<sub>6</sub>R<sub>7</sub>, C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl, C<sub>1</sub>-C<sub>6</sub> dihydroxyalkyl, or - (C<sub>1</sub>-C<sub>4</sub> alkyl)-morpholinyl.

#### 57. (Original) The compound according to claim 56, wherein

 $R_5$  is pyridyl  $C_1$ - $C_6$  alkyl, pyrimidinyl  $C_1$ - $C_6$  alkyl, or pyrazinyl  $C_1$ - $C_6$  alkyl, each of which is optionally substituted with 1, 2, or 3 groups that are independently hydroxy( $C_1$ - $C_4$ )alkyl,  $C_1$ - $C_4$  dihydroxyalkyl, OH, halogen, CF<sub>3</sub>, ( $C_1$ - $C_4$ )alkyl, OCF<sub>3</sub>, -NR<sub>6</sub>R<sub>7</sub>, -( $C_1$ - $C_4$  alkyl)-C(O)NR<sub>6</sub>R<sub>7</sub>, R<sub>6</sub>R<sub>7</sub>N-( $C_1$ - $C_6$  alkyl)-, or -C(O)NR<sub>6</sub>R<sub>7</sub>.

Claims 58-70 (Previously Canceled)

- 71. (Amended) The compound according to claim 13 selected from the group consisting of:
- 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N,4-dimethylbenzamide; Methyl 3-[4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate; Methyl 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate; Methyl 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzyl-6-oxopyrimidin-1(6H

difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate; 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide; 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-(methylthio)-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;

- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- (±) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[(methylamino)carbonyl]methyl}benzamide;
- (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[(methylamino)carbonyl]methyl}benzamide;
- (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[(methylamino)carbonyl]methyl}benzamide;
- (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- (+)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4- methylbenzamide;
- (-) 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N,4-dimethylbenzamide;
- (+) 3-[5-Bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N,4-dimethylbenzamide;
- (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[aminocarbonyl]methyl}benzamide;
- (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[aminocarbonyl]methyl}benzamide;
- ( $\pm$ ) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide;
- (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide;
- (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide;

( $\pm$ ) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2*R*)-2,3-dihydroxypropyl]-4-methylbenzamide;

- (-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2,3-dihydroxypropyl]-4-methylbenzamide;
- (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2,3-dihydroxypropyl]-4-methylbenzamide;
- (±) N-[(1S)-1-(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- (-) N-[(1S)-1-(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- (+) N-[(1S)-1-(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- ( $\pm$ ) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methylbenzamide;
- $\label{eq:continuous} \begin{tabular}{ll} $(\pm)$ 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-methylbenzamide; \end{tabular}$
- $\label{eq:continuous} (\pm)3\hbox{-}[5\hbox{-bromo-4-}[(2,4\hbox{-difluorobenzyl})\-oxy]-2\hbox{-methyl-}6\hbox{-oxopyrimidin-}1(6H)\-yl]-N-[(2S)-2\hbox{-hydroxypropyl}]-4\hbox{-methylbenzamide};$
- $\label{eq:continuous} $$(-)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2-hydroxypropyl]-4-methylbenzamide;$
- (+)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2-hydroxypropyl]-4-methylbenzamide;
- (±)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2-hydroxypropyl]-4-methylbenzamide;
- (-)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2-hydroxypropyl]-4-methylbenzamide;
- (+)3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2-hydroxypropyl]-4-methylbenzamide;
- (±) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;

(-) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;

- (+) 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;
- (±) N-[(1S)-1-(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- (-) N-[(1S)-1-(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- (+) N-[(1S)-1-(aminocarbonyl)propyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[1-(aminocarbonyl)methyl]-4-methylbenzamide;
  - 3-[4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[(methylamino)carbonyl]methyl}benzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide;
- N-[(1S)-1-(aminocarbonyl)ethyl]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-methylbenzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[1-(aminocarbonyl)methyl]-N,4-dimethylbenzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2,3-dihydroxypropyl]-4-methylbenzamide;

N-[(1R)-1-(aminocarbonyl)-2-hydroxyethyl]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;

- N-[(1R)-1-(aminocarbonyl)ethyl]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(1S)-2-hydroxy-1-methylethyl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N,4-dimethylbenzamide;
- N-[1-(aminocarbonyl)methyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- N-[(1R)-1-(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- N-[(1S)-1-(aminocarbonyl)propyl]-3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2-hydroxypropyl]-4-methylbenzamide;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2-hydroxypropyl]-4-methylbenzamide;
- 5-chloro-6-[(2,4-difluorobenzyl)oxy]-3-(5-{[(3S)-3-hydroxypyrrolidin-1-yl]carbonyl}-2-methylphenyl)pyrimidin-4(3H)-one;
- 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-methoxyethyl)-4-methylbenzamide;
- 5-chloro-6-[(2,4-difluorobenzyl)oxy]-3-(5-{[(3R)-3-hydroxypyrrolidin-1-yl]carbonyl}-2-methylphenyl)pyrimidin-4(3H)-one;
- 3-[4-[(2,4-difluorobenzyl)oxy]-5-ethyl-6-oxopyrimidin-1(6H)-yl]-N-[(1R)-2-hydroxy-1-methylethyl]-4-methylbenzamide;
- methyl 3-[4-[(2,4-difluorobenzyl)oxy]-5-iodo-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate;

methyl 3-[4-[(2,4-difluorobenzyl)oxy]-5-ethyl-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate;

- 3-[4-[(2,4-difluorobenzyl)oxy]-5-ethyl-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-(methylamino)-6-oxopyrimidin-1(6H)-yl]-N,4-dimethylbenzamide;
- methyl 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-(methylamino)-6-oxopyrimidin-1(6H)-yl]-4-methylbenzoate;
- N-[1-(aminocarbonyl)methyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-(methylamino)-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-(methylamino)-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[(methylamino)carbonyl]methyl}benzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2,3-dihydroxypropyl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2,3-dihydroxypropyl]-4-methylbenzamide;
- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;
- N-[(1S)-1-(aminocarbonyl)ethyl]-3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-4-methylbenzamide;

3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2-hydroxypropyl]-4-methylbenzamide;

- 3-[5-bromo-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2-hydroxypropyl]-4-methylbenzamide;
- (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;
- (-) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;
- (+) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide;
- (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[aminocarbonyl]methyl}benzamide;
- (-)3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[aminocarbonyl]methyl}benzamide;
- (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[(methylamino)carbonyl]methyl}benzamide;
- (±) 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-4-methyl-N-{1-[(methylamino)carbonyl]methyl}benzamide;
- ± 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2S)-2-hydroxypropyl]-4-methylbenzamide;
- $\pm$  3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]-N-[(2R)-2-hydroxypropyl]-4-methylbenzamide;
  - 3-benzyl-6-(benzyloxy)-5-bromopyrimidin-4(3H)-one;
- 3-benzyl-6-(benzyloxy)-pyrimidin-4(3H)-one; 4-{[5-bromo-4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]methyl}-N-methylbenzamide; andmethyl 4-{[4-[(2,4-difluorobenzyl)oxy]-2-methyl-6-oxopyrimidin-1(6H)-yl]methyl}benzoate;
  - or their isomer and pharmaceutically acceptable salt thereof.

72. (Amended) A pharmaceutical composition comprising a compound of claim 71, or a pharmaceutically acceptable salt or tautomer thereof, in a pharmaceutically acceptable carrier.

- 73. (Amended) A method of treating arthritis in a subject, the method comprising treating a subject in need thereof having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Claim 71; or a pharmaceutically acceptable salt or tautomer thereof.
- 74. (Amended) A method of treating rheumatoid arthritis in a subject, the method comprising treating a subject <u>in need thereof</u> having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Claim 71; or a pharmaceutically acceptable salt or tautomer thereof.
- 75. (Amended) A method of treating asthma in a subject, the method comprising treating a subject in need thereof having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Claim 71; or a pharmaceutically acceptable salt or tautomer thereof.
- 76. (Amended) A method of treating chronic obstructive pulmonary disease (COPD) in a subject, the method comprising treating a subject in need thereof having or susceptible to such disorder or condition with a therapeutically-effective amount of a compound of Claim 71; or a pharmaceutically acceptable salt thereof.